The report "DNA Diagnostics Market by Product (Instruments, Reagents & Kits, Services & Software), Technology (PCR, Mass Spectroscopy, Microarrays), Application (Infectious Disease (Hepatitis, HIV, HPV), Oncology), Specimen (Blood, Urine) - Global Forecast to 2029", is projected to reach USD 21.2 billion by 2029 from USD 13.3 billion in 2024, at a CAGR of 9.7 % during the forecast period. Growth in this market is primarily driven by the ability of DNA diagnostics to identify the genetic predispositions and susceptibility to chronic diseases, allowing for personalized and preventive healthcare strategies. Additionally, government initiatives, schemes, or funding activities that support and promote innovation and development provide growth opportunities in the DNA diagnostics market.
Browse 350 market data Tables and 48 Figures spread through 347 Pages and in-depth TOC on "DNA Diagnostics Market by Product (Instruments, Reagents & Kits, Services & Software), Technology (PCR, Mass Spectroscopy, Microarrays), Application (Infectious Disease (Hepatitis, HIV, HPV), Oncology), Specimen (Blood, Urine) - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/dna-diagnostics-market-145577831.html
The reagents & kits segment is projected to register the highest CAGR in the forecasted period for DNA diagnostics market, by offering segment, in 2023
Based on offering, the global DNA diagnostics market is segmented into reagents & kits, instruments, and services & software. In 2023, the reagents & kits segment accounted for the largest share of the DNA diagnostics market. With the growing prevalence of diseases and the need for accurate and timely diagnoses, the volume of DNA diagnostic tests is consistently increasing. Reagents & kits play a critical role in accommodating this rise in test volumes, ensuring an ongoing demand for these consumables.
In 2023, the polymerase chain reaction (PCR) segment held the largest share of the DNA diagnostics market, by technology segment. Based on technology, the DNA diagnostics market is segmented into polymerase chain reaction (PCR), microarrays, in situ hybridization, sequencing technology, mass spectroscopy, and other technologies. In 2023, the polymerase chain reaction (PCR) segment accounted for the largest share of the DNA diagnostics market. PCR techniques have been well-established and widely adopted in the field of DNA diagnostics. The development and optimization of PCR protocols, along with the availability of reliable commercial kits and reagents, have made it easier for laboratories to implement PCR-based assays. The familiarity and accessibility of PCR technologies have contributed to their widespread use in DNA diagnostics.
The blood, serum, and plasma segment accounted for largest market share of DNA diagnostics market, by specimen, in 2023
Based on specimens, the DNA diagnostics market is segmented into blood, serum, and plasma, urine, and other specimens. In 2023, the blood, serum, and plasma segment accounted for the largest share of the DNA diagnostics market. As blood-based DNA diagnostics have demonstrated clinical utility across a broad range of applications, including genetic testing, infectious disease diagnosis, cancer diagnostics, and monitoring disease progression, this versatility and clinical efficacy have solidified blood samples as a preferred choice in many diagnostic scenarios.
The infectious disease diagnostic segment accounted for the largest share of the DNA diagnostics market, by application, in 2023
Based on applications, the DNA diagnostics market is segmented into infectious disease diagnostics, oncology testing, prenatal, pre-implantation, myogenic disorders, and other applications. In 2023, the infectious disease diagnostic segment accounted for the largest share of the DNA diagnostics market. Hepatitis, HIV, CT/NG, HIV, and HPV are the common infectious diseases for which DNA diagnostic tests are performed. The increasing incidence of sexually transmitted diseases, and hepatitis are major factors driving the demand for DNA diagnostic tests worldwide.
The diagnostic laboratories segment accounted for the largest share of the DNA diagnostics market, by end user, in 2023
Based on end users, the DNA diagnostics market is segmented into hospitals and clinics, diagnostic laboratories, and other end users. In 2023, the diagnostics laboratories segment accounted for the largest share of the DNA diagnostics market. Diagnostics laboratories offer a wide range of DNA diagnostic tests for various diseases and conditions. These tests can detect genetic disorders, infectious diseases, cancer markers, and other DNA biomarkers. The diversity of tests attracts a large number of patients and healthcare providers, contributing to the largest market share of this segment.
The Asia Pacific market is expected to witness the highest growth during the forecast period.
The global DNA diagnostics market is divided into six key regions: North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries. The Asia Pacific is projected to register the highest CAGR of 11.1% in the DNA diagnostics market during the forecast period. The high growth in the Asia Pacific market can be attributed to the increasing government efforts to grow awareness about early disease detection, rising per capita income, the increasing expansion of private-sector hospitals to rural areas in various Asia Pacific countries, and the increasing presence of high-growth markets in the region.
Prominent players in the market include Illumina, Inc. (US), Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Hologic, Inc. (US), QIAGEN (Germany), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), Revvity, Inc. (US), Siemens Healthineers AG (Germany), Agilent Technologies, Inc. (US), Becton, Dickinson and Company (BD) (US), DiaSorin S.p.A. (Italy), Grifols S.A. (Spain), Quidelortho Corporation (US), Amoy Diagnostics Co., Ltd (China), Molbio Diagnostics Pvt. Ltd. (India), Biocartis (Belgium), Exact Sciences Corporation (US), TBG Diagnostics Ltd (Australia), Genetic Signatures (Australia), and Vela Diagnostics (Singapore).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com